Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study

References

• Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investigat Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet (London, England). 2007;370(9583):263–271.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.
   PubMed Web of Science ®Google Scholar
• Raut AS, Prabhu RH, Patravale VB. Psoriasis clinical implications and treatment: a review. Crit Rev Ther Drug Carrier Syst. 2013;30(3):183–216.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51(5):704–708.
   PubMed Web of Science ®Google Scholar
• Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007;57(6):963–971.
   PubMed Web of Science ®Google Scholar
• Menter A. Psoriasis. 1st ed.: London: Manson Publishing; 2010.
   Google Scholar
• Agency EM. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis; 2004; [cited 2019 Dec 27]. Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf
   Google Scholar
• Excellence NIfHaC. Psoriasis: assessment and management; 2012; [cited 2019 Dec 27]; Clinical guideline [CG153]]. Available from: https://www.nice.org.uk/guidance/cg153.
   Google Scholar
• Koek MB, Buskens E, van Weelden H, et al. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). BMJ (Clinical Research ed). 2009;338:b1542–b1542.
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treatment. 2015;26(1):23–31.
   PubMed Web of Science ®Google Scholar
• Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2(1):12.
   PubMedGoogle Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999;141(4):698–702.
   PubMed Web of Science ®Google Scholar
• Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investigat Dermatol Symp Proc. 2004;9(2):169–180.
   PubMed Web of Science ®Google Scholar
• Shikiar R, Bresnahan BW, Stone SP, et al. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1(1):53.
   PubMedGoogle Scholar
• Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006;4:71.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, et al. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology (Basel, Switzerland). 2008;216(3):260–270.
   PubMed Web of Science ®Google Scholar
• Torii H, Sato N, Yoshinari T, et al. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. J Dermatol. 2012;39(3):253–259.
   PubMed Web of Science ®Google Scholar
• Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatol Treat. 2015;26(3):235–239.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLOS One. 2012;7(12):e52935.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Giglio Girolomoni DM. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11):E2427.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648.
   PubMed Web of Science ®Google Scholar
• Colombo MD, Cassano N, Bellia G, et al. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. TheScientificWorldJournal. 2013;2013:1–11.
   Google Scholar
• Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349(7):658–665.
   PubMed Web of Science ®Google Scholar
• Maza A, Montaudie H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 2):19–27.
   PubMed Web of Science ®Google Scholar
• Shintani Y, Kaneko N, Furuhashi T, et al. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis. J Dermatol. 2011;38(10):966–972.
   PubMed Web of Science ®Google Scholar
• Yoon HS, Youn JI. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatol Treat. 2007;18(5):286–290.
   PubMed Web of Science ®Google Scholar
• Arnold T, Schaarschmidt ML, Herr R, et al. Drug survival rates and reasons for drug discontinuation in psoriasis. J German Soc Dermatol. 2016;14(11):1089–1099.
   PubMed Web of Science ®Google Scholar